Merus Announces Publication of Abstracts on MCLA-129 for

-  Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m....

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Netherlands ,Zenocutuzumab Zeno ,European Society For Medical Oncology ,Early Access Program ,Sasia Congress ,Development Strategy ,Exchange Commission ,Company Conference Call ,European Society ,Medical Oncology ,Singapore December ,Bill Lundberg ,Chief Executive Officer ,Response Evaluation Criteria ,Solid Tumors ,Thoracic Cancer ,Conference Call ,Private Securities Litigation Reform Act ,Quarterly Report ,Nasdaq Mrus ,Merusnv ,Serus ,Merus Nv ,